Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in Japan

Abolarinwa, B.A., Shaw, M.K., and Lee,

C.H. (2021). Perspectives on challenges to

cell therapy development in Taiwan:

strengthening evidential standards and

ways forward. Front. Bioeng. Biotechnol.

9, 789043. https://doi.org/10.3389/fbioe.

2021.789043.

Fu, W., Smith, C., Turner, L., Fojtik, J., Pacyna, J.E., and Master, Z. (2019). Characteristics and scope of training of clinicians

participating in the US direct-to-consumer

marketplace for unproven stem cell interventions. JAMA 321, 2463–2464. https://

doi.org/10.1001/jama.2019.5837.

2r9852000002zggt-att/2r9852000002zgkl.

pdf.

Health Science Council, Regenerative Medicine Evaluation Committee. The interim

report on the review of the law for enforcement of act on the safety of regenerative

medicine 5 years after its enforcement

(2019). https://www.mhlw.go.jp/content/

000581069.pdf.

International Society for Stem Cell

Research (2021). ISSCR Guidelines for

stem cell research and clinical translation.

https://www.isscr.org/guidelines.

Konomi, K., Tobita, M., Kimura, K., and

Sato, D. (2015). New Japanese initiatives

on stem cell therapies. Cell Stem Cell 16,

350–352. https://doi.org/10.1016/j.stem.

2015.03.012.

MHLW (2018). The list of emergency orders

and improvement orders. https://www.

mhlw.go.jp/file/06-Seisakujouhou-108000

00-Iseikyoku/0000207357.pdf.

MHLW (2021a). Report on quality improvement project by the certified special committee for regenerative medicine. https://www.

mhlw.go.jp/content/10808000/000836760.

pdf.

MHLW (2021b). RM provision criteria

checklist. https://www.mhlw.go.jp/content/

10800000/000506053.pdf.

Mullard, A. (2011). The mediator scandal

has rocked the French medical community.

Lancet 377, 890–892. https://doi.org/10.

1016/S0140-6736(11)60334-6.

Fujita, M., Hatta, T., and Ide, K. (2022).

Current status of cell-based interventions

in Japan. Cell Stem Cell 29, 1294–1297.

https://doi.org/10.1016/j.stem.2022.08.

003.

Lysaght, T., and Sugii, S. (2016). Uncertain

oversight of regenerative medicines in

Japan under the ASRM. Cell Stem Cell 18,

438–439. https://doi.org/10.1016/j.stem.

2016.03.007.

Murdoch, B., Zarzeczny, A., and Caulfield,

T. (2018). Exploiting science? A systematic

analysis of complementary and alternative

medicine clinic websites’ marketing of

stem cell therapies. BMJ Open 8, e019414.

https://doi.org/10.1136/bmjopen-2017-01

9414.

Health Science Council (2013). Expert

committee on safety assurance and promotion of RM. In Report ‘‘Building a framework for safety assurance and promotion of

RM’’. https://www.mhlw.go.jp/stf/shingi/

McKee, S. (2013). French Drugs Regulator

Facing Manslaughter Charge (Pharma

Times). https://www.pharmatimes.com/

news/french_drugs_regulator_facing_man

slaughter_charge_1004699.

Tsai, T.H., Ling, T.Y., and Lee, C.H. (2020).

Adoption of regulations for cell therapy

development: linkage between Taiwan

and Japan. Clin. Transl. Sci. 13, 1045–

1047. https://doi.org/10.1111/cts.12813.

Stem Cell Reports j Vol. 18 j 613–617 j March 14, 2023 617

...